LYCIA THERAPEUTICS, INC. LYCA.US

Lycia Therapeutics is a clinical-stage biotechnology company that develops novel therapeutics built on its proprietary LYTAC (Lysosomal Targeting Chimera) platform. The company's core business is focused on degrading disease-causing extracellular proteins - proteins that circulate in blood or are bound to cell surfaces - which to date are poorly addressed by traditional inhibitors.

The lead programs include LCA-0061, a cataLYTAC degrader targeting immunoglobulin E (IgE) for allergic diseases, including food allergy, and LCA-0321, a LYTAC degrader designed to eliminate thyroid-stimulating hormone receptor autoantibodies in Graves' disease.

In addition to these lead assets, Lycia's pipeline includes LCA-0062, a fast-follower bispecific IgE degrader currently in IND-enabling development. The platform strategy emphasizes modular design of extracellular protein degraders to allow deep, durable elimination of targets, rather than mere inhibition.

Preclinical head-to-head studies for LCA-0061 reportedly showed greater depth and duration of IgE reduction compared with approved and investigational blockers. Lycia is headquartered in South San Francisco, California, and was founded in 2019.

Its operations include discovery research, preclinical and early clinical development, regulatory affairs, and contract manufacturing via third-party organizations for drug substance and drug product.

It has not yet generated revenue from product sales. Its initial public offering was completed in late October 2026, and its common stock now trades on the Nasdaq Global Select Market. The company is incorporating its therapeutics into indications with well-validated disease biology and relatively large patient populations, primarily autoimmune, inflammatory and allergic diseases.